Therapeutic effects of a new quinolone, DU-6859a, on polymicrobial infections in a newly designed model of rat uterine endometritis.
We evaluated the efficacy of a new quinolone, DU-6859a, using a new model of rat uterine endometritis. Rats were infected with mixed inocula of Escherichia coli and Bacteroides fragilis. The MICs of DU-6859a and levofloxacin against E. coli were 0.025 and 0.05 mg/L, respectively; those against B. fragilis were 0.20 and 0.39 mg/L, respectively. Immediately after inoculating 10(5) cfu/rat of each organism, DU-6859a or levofloxacin (20 mg/kg po bid or tid, respectively, for 3 days) was administered and compared with the untreated group. The viable cell counts of E. coli and B. fragilis in the DU-6859a- and levofloxacin-treated groups were significantly lower than those in the untreated group. These results suggest that DU-6859a would be useful for treating polymicrobial infections in uterine endometritis.
Mikamo
H
H
Department of Obstetrics and Gynaecology, School of Medicine, Gifu University, Japan.
Kawazoe
K
K
Sato
Y
Y
Izumi
K
K
Tamaya
T
T
D000818:Animals; D000890:Anti-Infective Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001441:Bacteroides fragilis / Q000472:pathogenicity; D004195:Disease Models, Animal; D004359:Drug Therapy, Combination / Q000008:administration & dosage / Q000627:therapeutic use*; D004716:Endometritis / Q000188:drug therapy* / Q000382:microbiology / Q000473:pathology; D004926:Escherichia coli / Q000472:pathogenicity; D005260:Female; D024841:Fluoroquinolones; D064704:Levofloxacin; D015242:Ofloxacin / Q000008:administration & dosage / Q000627:therapeutic use; D015363:Quinolones / Q000008:administration & dosage / Q000627:therapeutic use*; D051381:Rats; D017207:Rats, Sprague-Dawley
D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D015363:Quinolones; D064704:Levofloxacin; C076246:sitafloxacin; D015242:Ofloxacin